GlobalData on MSN2d
JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole
AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...
AbbVie's SWOT analysis: stock outlook amid Humira erosion and pipeline growth
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...
FiercePharma2d
JPM25, Day 3: AbbVie's 'clear runway to growth' allows it to focus on early-stage acquisitions
Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...
Healio1d
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...
PharmiWeb4d
AbbVie’s SKYRIZI® (risankizumab) Accepted by the S…
Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative ColitisPRESS RELEASE – For UK consumer health, medical and trade media onlyRisankizumab will be ...